• ABOUT
  • Company Overview
  • Management
  • Contact Information
• PRODUCTS
  • Product Strategy
  • Candidates
  • TRU-015 (Rheumatoid Arthritis)
  • SBI-087 (Rheumatoid Arthritis)
  • SBI-087 (Systemic Lupus Erythematosus)
  • TRU-016 (B-Cell Malignancies)
  • DRACO (Anti-CD3 SMIP)
  • X1 (TNF-based SCORPION)
  • X2 (CTLA4-based SCORPION)
  • Product Technology
  • SMIP™ Therapeutics
  • SCORPION™ Therapeutics
  • TRU-ADhanCe™ Technology
  • Patient Center
  • Rheumatoid Arthritis (RA)
  • Leukemia
  • Lymphoma
  • Lupus
• PARTNERSHIPS
  • Current Partnerships
• INVESTORS
  • Corporate Governance
  • Stock Information
  • Stock Performance
  • Historic Stock Lookup
  • Investment Calculator
  • Dividend History
  • Analyst Coverage
  • Financials
  • SEC Filings
  • Quarterly Results
  • Annual Reports
  • News & Events
  • Press Releases
  • Events & Presentations
  • Stockholder Services
  • Investor FAQs
  • Contact Us
• MEDIA
• CAREERS
  • Joining the Trubion Team
  • Job Openings
  • Culture and Benefits
•  

PRODUCT CANDIDATES

TRU-015 for the Treatment of Rheumatoid Arthritis

SBI-087 for the Treatment of Rheumatoid Arthritis

SBI-087 for the Treatment of Systemic Lupus Erythematosus

TRU-016 for the Treatment of B-Cell Malignancies

Return to Pipeline

Copyright 2002–2008 Trubion Pharmaceuticals Inc. All rights reserved.

Site Map | Terms of Use